On March 27, 2023 Avacta Group plc, a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, reported that it will present a poster entitled ‘AVA3996, a novel pre|CISION medicine, targeted to the tumor microenvironment via Fibroblast Activation Protein-alpha (FAP-a) mediated cleavage’, at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2023 Annual Meeting, taking place at Orange County Convention Center, Orlando, Florida on 16 April (Press release, Avacta, MAR 27, 2023, View Source [SID1234629400]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster describes the data and pre-clinical rationale for the further development and disease positioning of the Company’s second pre|CISION candidate, AVA3996, a tumour microenvironment activated proteasome inhibitor. AVA3996 utilises Avacta’s pre|CISION platform to improve the therapeutic index and therefore utility of proteasome inhibitors in tumours with high FAP levels, including both solid and haematological tumours. AVA3996 has the potential to deliver efficacious levels of the proteasome inhibitor warhead directly to the tumour microenvironment while reducing systemic exposure and hence associated toxicities, such as peripheral neuropathy.
Attending the conference from Avacta will be Fiona McLaughlin – Chief Scientific Officer, Neil Bell – Chief Development Officer, David Jones – VP Biology and Francis Wilson – VP Chemistry.
Poster Presentation Title
AVA3996, a novel pre|CISION medicine, targeted to the tumor microenvironment via fibroblast activation protein-alpha (FAP-a) mediated cleavage
Session Category
Experimental and Molecular Therapeutics
Session Title
Targeting the Tumour Microenvironment
Session Date and Time
April 16, 2023 1:30 PM – 5:30 PM ET
Location
Orange County Convention Center, Section 20
Poster Board Number
17
Abstract Presentation Number
583
The abstract is available via the AACR (Free AACR Whitepaper) annual meeting website, here: View Source!/10828/presentation/2606
Copies of the poster will be available on Avacta’s website following the conference at: View Source
Alastair Smith, Avacta Chief Executive Officer, will provide a video presentation overview for investors examining the data presented in the poster. This will be available on 17th April at View Source